| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $7,016,933 | 10 | 100 |
| Freund John Gordon | director | 0 | $0 | 2 | $143,228 | $-143,228 |
| Lurker Nancy | director | 0 | $0 | 1 | $161,861 | $-161,861 |
| Balice-Gordon Rita J. | director | 0 | $0 | 1 | $171,673 | $-171,673 |
| BOHLIN GAREN G | director | 0 | $0 | 1 | $323,491 | $-323,491 |
| Dieter David | EVP & General Counsel | 0 | $0 | 1 | $488,099 | $-488,099 |
| Tupper Colleen | EVP & Chief Financial Officer | 0 | $0 | 1 | $1.22M | $-1.22M |
| Fallon John A. | director | 0 | $0 | 1 | $1.65M | $-1.65M |
| Dreyer Scott | EVP & Chief Commercial Officer | 0 | $0 | 2 | $2.87M | $-2.87M |
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. …
Over the last 12 months, insiders at Collegium Pharmaceutical, Inc. have bought $0 and sold $7.02M worth of Collegium Pharmaceutical, Inc. stock.
On average, over the past 5 years, insiders at Collegium Pharmaceutical, Inc. have bought $0 and sold $8.73M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $183,600 was made by Brannelly Paul (Executive Vice President & CFO) on 2017‑05‑12.
| 2026-05-18 | Sale | Freund John Gordon | director | 20 <0.0001% | $34.05 | $681 | -16.11% | |
| 2026-05-15 | Sale | Freund John Gordon | director | 4,127 0.013% | $34.54 | $142,547 | -16.03% | |
| 2026-05-13 | Sale | Lurker Nancy | director | 4,500 0.0143% | $35.97 | $161,861 | -17.92% | |
| 2026-05-11 | Sale | BOHLIN GAREN G | director | 8,700 0.0279% | $37.18 | $323,491 | -19.23% | |
| 2026-03-18 | Sale | Dieter David | EVP & General Counsel | 13,976 0.0442% | $34.92 | $488,099 | -4.51% | |
| 2026-03-03 | Sale | Dreyer Scott | EVP & Chief Commercial Officer | 49,976 0.1536% | $40.41 | $2.02M | -16.54% | |
| 2025-12-08 | Sale | Dreyer Scott | EVP & Chief Commercial Officer | 17,600 0.056% | $48.17 | $847,855 | -27.53% | |
| 2025-12-05 | Sale | Balice-Gordon Rita J. | director | 3,650 0.0113% | $47.03 | $171,673 | -27.51% | |
| 2025-11-12 | Sale | Fallon John A. | director | 34,853 0.1231% | $47.21 | $1.65M | -26.16% | |
| 2025-11-06 | Sale | Tupper Colleen | EVP & Chief Financial Officer | 30,000 0.1072% | $40.53 | $1.22M | -13.65% | |
| 2025-08-29 | Sale | Smith Thomas B | EVP and Chief Medical Officer | 17,478 0.0549% | $38.42 | $671,576 | -8.07% | |
| 2025-08-18 | Sale | Dreyer Scott | EVP & Chief Commercial Officer | 16,389 0.052% | $38.21 | $626,171 | -6.23% | |
| 2025-08-15 | Sale | SANTINI GINO | director | 5,405 0.0169% | $37.19 | $201,018 | -5.03% | |
| 2025-08-13 | Sale | Rubric Capital Management LP | 10 percent owner | 25,000 0.0793% | $37.85 | $946,250 | -5.31% | |
| 2025-08-13 | Sale | Dreyer Scott | EVP & Chief Commercial Officer | 4,861 0.0155% | $38.03 | $184,881 | -5.31% | |
| 2025-08-08 | Sale | Freund John Gordon | director | 11,659 0.0357% | $34.36 | $400,641 | +3.01% | |
| 2025-06-09 | Sale | Freund John Gordon | director | 6,601 0.0207% | $30.62 | $202,149 | +17.02% | |
| 2025-03-21 | Sale | Tupper Colleen | EVP & Chief Financial Officer | 6,396 0.0203% | $30.03 | $192,069 | +17.89% | |
| 2025-03-21 | Sale | Dreyer Scott | EVP & Chief Commercial Officer | 18,881 0.0599% | $30.03 | $566,983 | +17.89% | |
| 2025-03-20 | Sale | Tupper Colleen | EVP & Chief Financial Officer | 1,206 0.0038% | $30.00 | $36,181 | +18.31% |
| Freund John Gordon | director | 83952 0.2579% | $1.99M | 1 | 4 | +44.38% |
| Fallon John A. | director | 64634 0.1985% | $1.53M | 1 | 1 | +26.87% |
| Skyline Venture Partners V LP | 10 percent owner | 2949916 9.0612% | $70M | 1 | 0 | +44.38% |
| Heron Patrick J | 1887332 5.7973% | $44.79M | 1 | 0 | +44.38% | |
| Frazier Healthcare VI, L.P. | 10 percent owner | 1887332 5.7973% | $44.79M | 1 | 0 | +44.38% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1325253 4.0707% | $31.45M | 1 | 0 | +44.38% | |
| Brannelly Paul | Executive Vice President & CFO | 123436 0.3792% | $2.93M | 1 | 1 | +42.57% |
| Longitude Capital Partners, LLC | 10 percent owner | 45620 0.1401% | $1.08M | 1 | 1 | +44.38% |
| Hirsch David | director | 17117 0.0526% | $406,186.41 | 1 | 3 | +44.38% |
$1,279,728,023 | 131 | 10.76% | $3.05B | |
$14,599,168 | 59 | 12.79% | $1.66B | |
$102,709,455 | 46 | 30.55% | $1.45B | |
$73,762,556 | 45 | -9.99% | $2.17B | |
$98,035,963 | 43 | -10.97% | $486.79M |
| Increased Positions | 139 | +48.94% | 4M | +11.6% |
| Decreased Positions | 125 | -44.01% | 4M | -11.33% |
| New Positions | 51 | New | 852,762 | New |
| Sold Out Positions | 17 | Sold Out | 366,959 | Sold Out |
| Total Postitions | 298 | +4.93% | 37M | +0.26% |
| Blackrock, Inc. | $235,756.00 | 16.18% | 5.18M | -163,812 | -3.07% | 2025-09-30 |
| Rubric Capital Management Lp | $128,690.00 | 8.83% | 2.83M | -331,245 | -10.49% | 2025-09-30 |
| Eventide Asset Management, Llc | $108,858.00 | 7.47% | 2.39M | -250,489 | -9.48% | 2025-09-30 |
| Vanguard Group Inc | $101,367.00 | 6.96% | 2.23M | -21,833 | -0.97% | 2025-09-30 |
| Renaissance Technologies Llc | $72,811.00 | 5% | 1.6M | +78,019 | +5.13% | 2025-09-30 |
| Fuller & Thaler Asset Management, Inc. | $68,417.00 | 4.7% | 1.5M | +71,645 | +5.01% | 2025-09-30 |
| Principal Financial Group Inc | $59,634.00 | 4.09% | 1.31M | -157,104 | -10.71% | 2025-09-30 |
| State Street Corp | $58,912.00 | 4.04% | 1.29M | -60,506 | -4.47% | 2025-09-30 |
| Invesco Ltd. | $58,414.00 | 4.01% | 1.28M | -301,900 | -19.05% | 2025-09-30 |
| Janus Henderson Group Plc | $41,443.00 | 2.85% | 910,241 | +440,692 | +93.85% | 2025-09-30 |